Bionaut Labs Gets $43.2 Million for Its Small Drug Delivery Robots • TechCrunch

Bionaut Laboratories was founded in 2017. Arrived off sneak in March 2021, which plans to commercialize long-term research into drug delivery robots. Today, the startup based in Los Angeles announced its $20 million seed funding With $43.2 million Series BThe total increase was – you guessed right – $63.2million. Khosla Ventures was the leader of this round, which included new investors Deep Insights, OurCrowds, PSPRS and Sixty Degree Capital. Dolby Family Ventures received GICEV Family Ventures, Tintah Grace, Gaingels and Tintah Grace.

If you are familiar with robotics, you will be aware of the research done on tiny remote-controlled medical robots. Bionaut’s research has many deadlines. These include 2023 preclinical studies followed by clinical trials with humans in the next years.

“There has been a lack of innovation around treatments that cause great suffering, in large parts because of past failures which have frustrated even the most skilled researchers,” Michael Spiegelmacher, CEO and co-founder, stated in a statement. Bionaut Laboratories is committed to finding new treatments for these deadly diseases, which have been long overdue for a major breakthrough.

The startup’s namesake magnetically-driven robots are designed to deliver treatments to the midbrain — a more direct application than standard drugs delivered systemically (intravenously, orally, etc.). The company is interested in Huntington’s and Parkinson’s diseases, as well as other debilitating conditions.

This funding round will be used to fund therapies for brain cancers, malignant and aggressive glioma. Dandy Walker Syndrome. The money will also be used for research and development in its technology and to reach the above milestones.

Aviad Maizels, co-founder of PrimeSense (Israel-based 3D visualization firm behind Microsoft Kinect), was once co-owner of Spiegelmacher. Apple acquired this company in 2013 and used it as the basis of its Face ID technology.